BRTX

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company's vertically integrated regenerative medicine platform.

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the appointment of Zachary Smith as Vice President of its Biocosmeceuticals Division, further strengthening the Company's commercial leadership team as it expands its presence within the regenerative aesthetics and advanced skincare market.

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment

Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety signals observed MELVILLE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX ), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, the Company's autologous hypoxic-cultured mesenchymal stem cell therapy for the treatment of chronic lumbar disc disease.

Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it will present new data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, taking place May 6-9 in Dublin, Ireland.

Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.